Spyre Therapeutics Jumps As SPY001 Meets Key Goal In Phase 2 SKYLINE Trial For Ulcerative Colitis

India, April 13 -- Spyre Therapeutics, Inc. (SYRE), a clinical-stage biotechnology company, announced positive 12-week induction data from Part A of the Phase 2 SKYLINE trial of SPY001, stating that it met the primary end point for the treatment of moderate-to-severely active ulcerative colitis (UC).

Following the news, SYRE is up 28.33%. at $65.81.

SPY001 is an extended half-life investigational antibody targeting a4ß7, an integrin central to immune cell trafficking to the gut. SKYLINE Trial Findings

SKYLINE is a two-part induction and maintenance platform trial of SPY001, SPY002, SPY003, and their pairwise combinations in patients with moderately to severely active ulcerative colitis.SKYLINE Part A is an open-label assessment of t...